ICICI Pru Pharma Healthcare And Diagnostics Fund
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Growthvine rating: 5/5 — ranked #3 of 84 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹43.49 (as of 2026-08-21) |
|---|
| AUM | ₹6,803 Cr |
|---|
| Expense ratio | 1.55% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Dharmesh Kakkad |
|---|
| Exit load | 1% for redemption within 15 days |
|---|
Performance & risk
| 5-year annualised return | 15.81% |
|---|
| Sharpe ratio | 1.02 |
|---|
| Standard deviation | 16.11% |
|---|
| Max drawdown | -20.72% |
|---|
| Alpha | 1.26 |
|---|
| Beta | 0.95 |
|---|
Over 5 years, captured 94.8% of NIFTY Pharma's upside and 83.4% of its downside.
Market cap allocation
| Large cap | 26.0% |
|---|
| Mid cap | 33.4% |
|---|
| Small cap | 40.5% |
|---|
Concentration
| Top 5 holdings | 39.2% |
|---|
| Top 10 holdings | 60.3% |
|---|
| Total holdings | 35 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 12.7%
- Dr. Reddys Laboratories Ltd. — 8.4%
- Cipla Ltd. — 6.6%
- Divis Laboratories Ltd. — 6.0%
- Mankind Pharma Limited — 5.5%
- Alkem Laboratories Limited — 5.1%
- Biocon Ltd. — 5.0%
- Cohance Lifesciences Limited — 3.9%
- Medplus Health Services Limited — 3.8%
- Syngene International Limited — 3.3%
Top sectors
- Pharma & Biotech — 76.2%
- Healthcare — 13.0%
- Retail — 5.5%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 9.2% | Q2 | #26 of 76 |
| 2025 | -0.8% | Q3 | #37 of 69 |
| 2024 | 48.1% | Q1 (Top) | #2 of 58 |
| 2023 | 41.3% | Q2 | #15 of 48 |
| 2022 | -8.5% | Q4 (Bottom) | #36 of 46 |